CA2188784A1 - O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them - Google Patents

O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them

Info

Publication number
CA2188784A1
CA2188784A1 CA002188784A CA2188784A CA2188784A1 CA 2188784 A1 CA2188784 A1 CA 2188784A1 CA 002188784 A CA002188784 A CA 002188784A CA 2188784 A CA2188784 A CA 2188784A CA 2188784 A1 CA2188784 A1 CA 2188784A1
Authority
CA
Canada
Prior art keywords
group
phenyl
cyclohexanol
trans
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002188784A
Other languages
French (fr)
Inventor
Eberhard Woitun
Roland Maier
Peter Muller
Rudolf Hurnaus
Michael Mark
Bernhard Eisele
Ralph-Michael Budzinski
Gerhard Hallermayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002188784A priority Critical patent/CA2188784A1/en
Publication of CA2188784A1 publication Critical patent/CA2188784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

The invention concerns O-acyl-4-phenyl-cyclohexanols of the general formula (I) in which n stands for the numbers 0 or 1, m stands for the numbers 1 or 2, p stands for the numbers 0 or 1, R1 and R2 each stand for hydrogen, lower alkyl, alkenyl or alkinyl, these groups possibly being further substituted or, together with the intermediate nitrogen atom, forming 5 to 7-member saturated, monocyclic, heterocyclic rings which may possibly be further interrupted by an oxygen or sulphur atom or an imino group, R3, R4, R5 and R6 stand for hydrogen or lower alkyl, R5 additionally also stands for lower alkoxy, R7 stands for hydrogen, cycloalkyl, phenyl or substituted phenyl, naphthyl, tetrahydronaphthyl, thienyl, furyl or pyridyl and A stands for a chemical bond or alkyl, alkenyl or alkinyl having up to 17 carbon atoms. The invention further concerns a method of preparing said compounds, medicaments containing said compounds and the use of said medicaments which are effective in cholesterol biosynthesis. The anti-hypercholesterolemic substances are used for the treatment and prevention of atherosclerosis and inhibit the enzyme 2,3-epoxysqualene-lanosterol-cyclase.

Description

I:lLE, ~H~S ~ N~E~
T~Al~JS~ATI~
64133.587 O-Acyl-4-phenyl-CYclalkanolsr their salts, medicaments containing such compounds, and their use, as well as a method of preparing them The present invention relates to O-acyl-4-phenyl-cycloalkanOlS, the salts thereof with physiologically acceptable organic and inorganic acids, processes for preparing these compounds and pharmaceutical compositions containing them and the use thereof.

The compounds according to the invention are inhibitors of cholesterol biosynthesis, more particularly inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase, a key enzyme in cholesterol biosynthesis. The compounds according to the invention are suitable for the treatment and prophylaxis of hyperlipidaemia, hypercholesterolaemia and atherosclerosis.
Other possible fields of application consist of the treatment of hyperproliferative skin and vascular disorders, tumours, gallstone problems and mycoses.

Compounds which intervene in cholesterol biosynthesis are of importance in the treatment of a number of syndromes.
~ Particular examples are hypercholesterolaemias and -hyperlipidaemias which are risk factors for the development of atherosclerotic vascular changes and their sequelae such as, for example, coronary heart disease, cerebral ischaemia, claudicatio intermittens and gangrene.

The significance of elevated serum cholesterol levels as a main risk factor in the occurrence of atherosclerotic vascular changes is generally recosnised. Extensive clinical trials have led to the finding that the risk of coronary heart disease can be reduced by lowering serum cholesterol (Current Opinion in Lipidology 2(4), 234 [1991~). Since the majority of cholesterol is synthesised in the body and only a small proportion is taken in with food, the inhibition of biosynthesis constitutes a particularly attractive method of lowering elevated cholesterol levels.

Other possible fields of application for cholesterol biosynthesis inhibitors consist of the treatment of hyperproliferative skin and vascular disorders as well as tumoral diseases, the treatment and prophylaxis of gallstone problems and use in mycoses. This latter case involves intervention in the ergosterol biosynthesis in fungal organisms, which proceeds to a considerable extent in the same way as cholesterol biosynthesis in mammalian cells.

Cholesterol or ergosterol biosynthesis proceeds, starting from acetic acid, via a large number of reaction steps. This multi-step process presents a series of possible interventions, of which the following may be mentioned by way of example:

For inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, ~-lactones and ~-lactams with a potential antihypercholesterolaemic activity may be mentioned (see J. Antibiotics 40, 1356 [1987], US-A-4,751,237, EP-A-0 462 667, US-A-4,983,597~.

Inhibitors of the enzyme HMG-CoA-reductase are 3,5-dihydroxycarboxylic acids of the statin type and the ~-lactones, of which lovastatin, simvastatin and pravastatin are used in the treatment of hypercholesterolaemia.

Other possible uses for these compounds are fungal infections (US-A-4,375,475, EP-A-0 113 881, US-A-5,106,992~, skin diseases (EP-A-0 369 263) and gallstone problems and tumoral diseases (US-A-5,106,992; Lancet 339, 1154-1156 [1992]).
Another possible therapy is the inhibition of the proliferation of smooth muscle cells using lovastatin ` - 21 88784 (Cardiovasc. Drugs. Ther. 5, Suppl. 3, 354 [1991]).

Inhibitors of the enzyme squalene-synthetase include, for example, isoprenoid-(phosphinylmethyl)phosphonates which have been described as suitable for the treatment of hypercholesterolaemia, gallstone problems and tumoral diseases in EP-A-0 409 181 and in J. Med. Chemistry 34, 1912 [1991], as well as the squalestatins with a cholesterol-lowering and antimycotic effect (J. Antibiotics 45, 639-647 [1992] and J.
Biol. Chemistry 267, 11705-11708 [1992].

Known inhibitors of the enzyme s~ualene-epoxidase are allylamines such as naftifin and terbinafin, which have been used in therapy as dru~s to combat fungal diseases, as well as the allylamine NB-598 which has an antihypercholesterolaemic effect (J. Biol. Chemistry 265, 18075-18078, [1990]) and fluorosqualene derivatives having a hypocholesterolaemic effect (US-A-5,011,859). In addition, piperidines and azadecalins having a potential hypocholesterolaemic and/or antifungal activity have been described, the mechanism of activity of which has not been adequately explained and which constitute squalene epoxidase and/or 2,3-epoxysqualene-lanosterol-cyclase inhibitors (EP-A-0 420 116, EP-A-0 468 434, US-A-5,084,461 and EP-A-0 468 457).

Examples of inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase include diphenyl derivatives (EP-A-0 464 465), aminoalkoxybenzyl derivatives (EP-A-0 410 359) and piperidine derivatives (J. Org. Chem. 57, 2794-2803, [1992]) which have an antifungal activity.
Moreover, this enzyme is inhibited in mammalian cells by decalins, azadecalins and indane derivatives (WO 89/08450, J.
Biol. Chemistry 254, 11258-11263 [1981], Biochem. Pharmacology 37, 1955-1964 [1988] and J 64 003 144) and also by 2-aza-2,3-dihydrosqualene and 2,3-epiminosqualene (Biochem. Pharmacology ` - 21 887~4 34, 2765-2777 [1985]), by squalene-oxide-epoxide-enol ethers (J. Chem. Soc. Perkin Trans. I, 1988, 461) and 29-methylidene-2,3-oxidosqualene (J. Amer. Chem. Soc. 113, 9673-9674 [1991]).

Finally, steroid derivatives having a potential antihyperlipaemic activity may also be mentioned as inhibitors of the enzyme lanosterol-14~-demethylase and at the same time they have an effect on the enzyme HMG-CoA-reductase (US-A-5,041,432, J. Biol. Chemistry 266, 20070-20078 [1991], US-A-5,034,548). Furthermore, this enzyme is inhibited by antimycotics of the azole type which constitute N-substituted imidazoles and triazoles. This category includes, for example, the antimycotics ketoconazole and fluconazole which are on the market.

The compounds of general formula I which follows are new. It has been found, surprisingly, that they are highly effective inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase (International Classification: EC5.4.99.7).

The enzyme 2,3-epoxysqualene-lanosterol-cyclase catalyses a key stage of cholesterol or ergosterol biosynthesis, namely the conversion of 2,3-epoxysqualene into lanosterol, the first compound with a steroid structure in the biosynthesis cascade.
Inhibitors of this enzyme lead one to expect the advantage of higher selectivity over inhibitors of earlier biosynthesis stages, such as, for example, HMG-CoA-synthesis and HMG-CoA-reduction, since the inhibition of these early biosynthesis stages leads to a reduction in biosynthetically formed mevalonic acid and, as a result, may have a negative effect on the biosynthesis of the mevalonic acid-dependent substances dolichol, ubiquinone and isopentenyl-t-RNA (cf. J. Biol.
Chemistry ~, 18075-18078 [1990]).

In the inhibition of biosynthesis stages after the conversion of 2,3-epoxysqualene into lanosterol there is the risk of the accumulation of intermediate products having a steroidal structure in the body and the triggering of toxic effects connected therewith. This has been described, for example, for triparanol, a desmosterol reductase inhibitor. This substance has had to be taken off the market owing to the formation of cataracts, ichthyosis and alopecia (mentioned in J. Biol. Chemistry 265, 18075-18078 [1990]).

As has already been explained, inhibitors of 2,3-epoxysqualene-lanosterol-cyclase have been individually described in the literature. However, the structures of these compounds are completely different from the structure of the compounds according to the invention which conform to general formula I hereinafter.

The invention relates to the preparation of antihypercholesterolaemic substances suitable for the treatment and prophylaxis of atherosclerosis and, compared with known active substances, characterised by an improved antihypercholesterolaemic activity with greater selectivity and hence increased safety. Since the compounds according to the invention are also able to inhibit ergosterol biosynthe~is in fungal organisms, thanks to their considerable effectiveness as inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase, they are also suitable for the treatment of mycoses.

The present invention relates to new O-acyl-4-phenyl-cycloalkanols of general formula I

` ~18~784 Rl 3 ~ (C~2~p wherein n denotes the number O or 1, m denotes the number 1 or 2, p denotes the number O or 1, R1 and R2, which may be identical or different, denote a hydrogen atom, a straight-chained or branched C16-alkyl group, a straight-chained or branched C3 -6 - alkenyl or alkynyl group, the double and triple bonds thereof being isolated from the nitrogen-carbon bond, whilst the above-mentioned alkyl, alkenyl and alkynyl groups may also be substituted by an amino, hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, and the above-mentioned amino, hydroxy, alkoxy, alkylcarbonyloxy and alkylcarbonylamino group may not be bound to an unsaturated carbon atom and may not be bound to the carbon atom in position 1, or Rl and R2 together with the nitrogen atom between them denote a 5- to 7-membered saturated monocyclic heterocyclic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed a methylene group in the 4-position may be replaced by an oxygen or sulphur atom or by an optionally alkyl-substituted imino group, R3 and R4, which may be identical or different, denote a hydrogen atom or a straight-chained or branched C14-alkyl 21 8~784 group, R5 denotes a hydrogen atom, a straight-chained or branched Cl4-alkyl group or a C14-alkoxy group, R5 denotes a hydrogen atom or a straight-chained or branched Cl4-alkyl group, R7 denotes a hydrogen atom, a C37-cycloalkyl group, a phenyl group optionally mono- or disubstituted by a fluorine, chlorine or bromine atom or by a hydroxy, alkyl, alkoxy, phenylalkoxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkylcarbonylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkylcarbonyloxy, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group, wherein the substituents may be identical or different and two adjacent hydrogen atoms in a phenyl group may be replaced by a methylenedioxy or 1,2-ethylenedioxy group, a phenyl group substituted by two chlorine or bromine atoms and an amino group, a naphthyl or tetrahydronaphthyl group, a thienyl, furyl or pyridyl group substituted by a halogen atom or by one or two alkyl groups, and A denotes a bond, a straight-chained or branched Cll7-alkylene group or a C2l7-alkenylene or alkynylene group, whilst all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, and any halogen atom mentioned hereinbefore may be a fluorine, chlorine or bromine atom, the enantiomers, diastereomers and geometric isomers thereof and the salts thereof, more especially for pharmaceutical use the physiologically acceptable salts with organic or inorganic acids.

`- 21 88784 The preferred compounds are those of general formula Ia ,. Rl~ R3 r(CH2)m\ 11 7 ~,R2 / l4 ~ ~ O-C-A-R (Ia) wherein n, m and p each denote the number 1, R1 and R2, which may be identical or different, denote a hydrogen atom, a straight-chained or branched C16-alkyl group, a straight-chained or branched C36-alkenyl or alkynyl group, the double and triple bonds thereof being isolated from the nitrogen-carbon bond, whilst the above-mentioned alkyl, alkenyl and alkynyl groups may be substituted by an amino, hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, and the above-mentioned amino, hydroxy, alkoxy, alkylcarbonyloxy and alkylcarbonylamino group may not be bound to an unsaturated carbon atom and may not be bound to the carbon atom in position 1, or R1 and R2 together with the nitrogen atom between them denote a 5- to 7-membered saturated monocyclic heterocyclic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed a methylene group in the 4-position may be replaced by an oxygen or sulphur atom or by an optionally alkyl-substituted imino group, R3 to R6, which may be identical or different, each denote a hydrogen atom or a methyl group, R7 denotes a hydrogen atom, a C37-cycloalkyl group, a phenyl `- 21 887~4 group optionally mono- or disubstituted by a fluorine, chlorine or bromine atom or by a hydroxy, alkyl, alkoxy, phenylalkoxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkylcarbonylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkylcarbonyloxy, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group, whilst the substituents may be identical or different and two adjacent - ~ hydrogen atoms in a phenyl group may be replaced by a methylenedioxy or 1,2-ethylenedioxy group, a phenyl group substituted by two chlorine or bromine atoms and an amino group, a naphthyl or tetrahydronaphthyl group, a thienyl, furyl or pyridyl group substituted by a chlorine or bromine atom or by one or two alkyl groups, and A denotes a bond, a straight-chained or branched C11O-alkylene group or a C2l0-alkenylene or alkynylene group, wherein all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers thereof and the salts thereof, particularly for pharmaceutical use the physiologically acceptable salts thereof with inorganic or organic acids.

Particularly preferred compounds are those of general formula Ia wherein n, m and p each denote the number 1, R1 denotes a hydrogen atom, a straight-chained or branched Cl4-alkyl group which may be substituted by an aminocarbonyl group or in the 2-, 3- or 4-position by a hydroxy or alkoxy group, or a 2-propenylene group, and 21 887~4 R2 denotes a hydrogen atom, a Cl4-alkyl group or a 2-propenylene group, or R1 and R2 together with the nitrogen atom between them denote a 5- or 6-membered saturated monocyclic heterocyclic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed, a methylene group in the 4-position may be replaced by an oxygen atom or by an optionally alkyl-~ ~I substituted imino group, R3 to R6 each denote a hydrogen atom, R7 denotes a hydrogen atom, a C36-cycloalkyl group, a phenyl group optionally monosubstituted in the 4-position by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, phenyl, nitro or trifluoromethyl group, a phenyl group disubstituted by two chlorine atoms, one chlorine atom and an alkyl or amino group or two alkoxy groups, a phenyl group trisubstituted by two chlorine atoms and an amino group, a 3,4-methylenedioxyphenyl group, a naphthyl or tetrahydronaphthyl group, a 2-furyl group or a 2-thienyl group optionally substituted by a chlorine atom in the 5-position or a 3-pyridyl group, A denotes a bond, a straight-chained or branched C16-alkylene group or a C25-alkenylene group, whilst all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers thereof and the salts thereof, more particularly for pharmaceutical use the physiologically acceptable salts thereof with inorganic or organic acids.

Most particularly preferred compounds are those of general 21 ~784 formula Ia whereln n, m and p each denote the number 1, R1 denotes a hydrogen atom, a straight-chained or branched Cl4-alkyl group which may be substituted by an aminocarbonyl group or, in the 2-, 3- or 4-position, by a hydroxy or alkoxy group, or a 2-propenylene group, R2 denotes a hydrogen atom or a C14-alkyl group, R3 to R6 each denote a hydrogen atom, R7 denotes a phenyl group optionally substituted in the 4-position by a fluorine, chlorine or bromine atom or by a methyl, trifluoromethyl, methoxy, phenyl or nitro group, a 3,4-dichlorophenyl, 2,4-dichlorophenyl, 4-chloro-3-methylphenyl, 4-amino-3-chlorophenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-amino-3,5-dichlorophenyl or 2-naphthyl group, and A denotes a bond, a straight-chained or branched C1s-alkylene group or a C23-alkenylene group, wherein all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers thereof and the salts thereof, particularly for pharmaceutical use the physiologically acceptable salts thereof with inorganic or organic acids, and in particular the compounds (1) cis-0-(4-chlorobenozyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (2) cis-0-(4-phenyl-3-butenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (3) trans-0-(4-chlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (4) cis-0-(5-methylhexanoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (5) trans-0-(2-phenylpropionyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (6) trans-0-(4-fluorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (7) trans-0-(3,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (8) cis-0-(4-fluorocinnamoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (9) trans-0-(p-tolylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (10) trans-0-(4-[trifluoromethyl]-phenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (11) trans-0-(2-naphthylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (12) trans-0-(4-nitrophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (13) trans-0-(4-bromophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (14) trans-0-(2,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (15) trans-0-([4-amino-3-chlorophenyl]acetyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol (16) trans-0-(4-methoxyphenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol, (17) trans-0-(4-chlorophenylacetyl)-4-(4-methylaminomethyl-phenyl)-cyclohexanol, and the salts thereof.

Methods of preparation:
The compounds of formula I may be prepared, for example, by the following methods:

a) By reacting a 4-phenylcycloalkanol of general formula II

.-R \
N ~ (C)n ~ ~ ~ 2)m\
-R2 / R4 ~ (S~2) wherein n, m, p and R1 to R6 are as hereinbefore defined, with a carboxylic acid or the reactive derivatives thereof of general formula III

21 ~87~4 R7 - A - COX (III) wherein R7 and A are as hereinbefore defined and X denotes a hydroxy group or a reactive leaving group, e.g. a halogen atom, such as a chlorine or bromine atom, a trimethylsilyloxy group, a sulphonyloxy group, e.g. the p-toluenesulphonyloxy group, an N-heteroaryl group, e.g. the 1-imidazolyl or 1-benzotriazolyl ~ i group, or an O-isourea group, e.g. the O-(N,N'-dicyclohexyl)-lsourea group.

The reaction is conveniently carried out in a solvent such as benzene, toluene, xylene, diisopropylether, dioxan, tetrahydrofuran, dimethylformamide, dichloromethane or chloroform and optionally in the presence of a base such as triethylamine, pyridine or 4-dimethylaminopyridine, or in the presence of an acid, particularly if X in the general formula III denotes a hydroxy group, e.g. in the presence of boron trifluoride etherate or an acid cation exchanger at a temperature between -10 and 150C, but preferably at a temperature between -10 and 80C.

If the groups R1 and/or R2 contain free hydroxy, amino or carboxy groups, it is advisable to protect them in a suitable manner before the reaction, e.g. by converting the hydroxy into an ether group, e.g. a 2-methoxyethoxymethyl, tert.-butyl or benzylether group, the amino into a carbamate group, e.g. a trichloroethyl, 9-fluorenylmethyl or 2,4-dichlorobenzyl-carbamate group and the carboxyl into an ester group, e.g. a 2,2,2-trichloroethyl, tert.-butyl or benzylester group, and cleaving the protective groups by known methods once the reaction has ended.

b) By reacting an O-acyl-4-phenylcycloalkanol of general formula IV

21 ~8784 Y ~ (C)n ~ (C~2 m ~ o-C-A-R7 (IV) whereln n, m, p, R3 to R7 and A are as hereinbefore defined and Y denotes a reactive leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a sulphonyloxy group, e.g.
a methylsulphonyloxy group, with an amine of general formula V

Rl ~ (V) : NH
' R2/
wherein R1 and R2 are as hereinbefore defined.

The reaction is conveniently carried out in a suitable solvent such as ethanol, tert.-butanol, dimethylformamide or tetrahydrofuran, optionally in the presence of a base such as potassium carbonate, sodium ethoxide, potassium tert.butoxide or sodium hydride, and optionally under phase transfer conditions, at a temperature between 0 and 100C.

c) In order to prepare compounds of general formula I wherein Rl is as hereinbefore defined and R2 denotes a straight-chained or branched Cl6-alkyl group which may be substituted by a hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, wherein the hydroxy, alkoxy, alkylcarbonyloxy or - 21 ~8784 alkylcarbonylamino group is not bound to the carbon atom in position 1:

reacting an O-acyl-4-phenylcycloalkanol of general formula VI
Rl\ R3 R ~ ~CH ) wherein n, m, p, R3 to R7 and A are as hereinbefore defined and R1 has the meanings given above, with a compound of general formula VII
R2l z1 (VII) wherein R2' denotes a straight-chained or branched C16-alkyl group which may be substituted by a hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, wherein the hydroxy, alkoxy, alkylcarbonyloxy or alkylcarbonylamino group is not bound to the carbon atom in position 1, and Z1 denotes a reactive leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a sulphonyloxy group, e.g. a methylsulphonyloxy group.

The reaction is conveniently carried out in a solvent or mixture of solvents such as ethanol, tert.-butanol, tetrahydrofuran, dimethylsulphoxide or dimethylformamide, optionally in the presence of an acid binding agent, such as sodium carbonate, potassium carbonate, sodium hydroxide, sodium hydride, sodium methoxide, potassium tert.-butoxide, triethylamine or pyridine, wherein the latter two may `- 21 88784 simultaneously be used as solvent, optionally under phase transfer conditions, preferably at temperatures between 0 and 100C, e.g. at temperatures between 20 and 50C.

In the reactions described above, any reactive groups present such as hydroxy, amino, alkylamino, imino or carboxyl groups may be protected during the reaction by conventional protecting groups which are cleaved again once the reaction has ended.

For example, a protective group for a hydroxy group might be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert.-butyl, 2-methoxyethoxymethyl, benzyl or tetrahydropyranyl group, a protecting group for an amino, alkylamino or imino group might be an acetyl, benzoyl, ethoxycarbonyl or benzyl group and a protecting group for a carboxyl group might be a 2,2,2-trichloroethyl, tert.-butyl or benzylester group.

The optional subsequent cleaving of any protecting group used is preferably carried out by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as hydrochloric or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide at temperatures between 0 and 100C, preferably at the boiling temperature of the reaction mixture. However, a benzyl group is preferably cleaved by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50C, but preferably at ambient temperature, under a hydrogen pressure of 1 to 7 bar, but preferably 3 to S bar.

The compounds of general formula I prepared by the above methods may be purified and isolated using known methods, e.g.
crystallisation or chromatography.

In addition, the compounds of general formula I obtained may if desired be converted into the acid addition salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Suitable acids include, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

In the compounds of formula I according to the invention, stereoisomers such as diastereomers, geometric isomers or optical isomers may occur, depending on the position of the substituents on the cycloalkane ring or the form of the substituents Rl to R7. The invention includes both the pure stereoisomers and the mixtures thereof.

Start; ng compol~nds:

The starting compounds of general formula II may be prepared by the following method, for example:

1. By reduction of 4-phenylcycloalkanones of general formula VIII

.,Rl\ l3 ; - (C) ~ (C 2)m wherein n, m, p and Rl to R6 are as hereinbefore defined.

- ~ 21 88784 By a suitable choice of reducing agents, e.g. sodium borohydride or lithium tri-sec.-butyl-borohydride (L-selectrides) the reaction may be steered so as to produce mainly the e,e-isomer or the e,a-isomer of a compound of general formula II.

The ketones of general formula VIII may be prepared by known methods, e.g. by reacting monoethylene ketals of general formula IX

~ (C 2)m X ~ (IX) with an organometallic compound of general formula X

R \ R

~R2 / 14 ~ Me (X) wherein n and R1 to R5 are as hereinbefore defined and Me denotes a lithium atom or a group -MgHal, wherein Hal is a halogen atom, preferably a chlorine atom, with subsequent cleavage using water, hydrogenation of the resulting double bond and hydrolysis of the ketal grouping.

The process may be modified so that a ketone of general formula VIII wherein R6 denotes a hydrogen atom is converted, after the above reaction æequence has been carried out, into a - 21 ~8784 ketone of general formula VIII wherein R denotes a C14-alkyl group, e.g. by alkylation of the ketone-enolate ion.

Another method of preparing compounds of general formula VIII
consists of Dieckmann cyclisation of dicarboxylic acid esters of general formula XI
.R2 R3 R3/ IG~ ~ m COOR (XI) wherein n, m, p and R1 to R6 are as hereinbefore defined and R8 and R9, which may be identical or different, denote an alkyl, aralkyl or aryl group, and subsequent saponification and decarboxylation by known methods.

2. The starting compounds of general formula IV may be prepared, for example, by halomethylation of O-acyl-4-phenylcycloalkanols of general formula XII

~ ~ - o-C-A-R7 (XII) - ~ ~t(C~2)P

wherein m, p, Rs to R7 and A are as hereinbefore defined, with a corresponding aldehyde and hydrogen halide, e.g. hydrogen chloride or hydrogen bromide, in the presence of a Friedel ` - 21 88784 Crafts catalyst e.g. zinc chloride, and optional subsequent replacement of the halogen atom by another suitable reactive leaving group.

3. The starting compounds of general formula VI may be prepared, for example, from O-acyl-4-phenyl-cycloalkanols of general formula XIII

R \ 13 N ~ (C)n ~ ~ ( 2)m\ 11 7 z2 / R4 ~ ~ O-C-A-R (XIII) wherein n, m, p, R1, R3 to R7 and A are as hereinbefore defined and Z2 denotes a suitable protective group, by cleaving this protective group. An example of a protecting group may be a tert.-butoxycarbonyl, 1-(3,5-di-tert.-butylphenyl)-1-methylethoxycarbonyl or 2-(4-pyridyl)ethoxycarbonyl group.
The compounds of general formula XIII may be synthesised, for example, using the method described in Process 1.

The starting compounds of formulae III and V are known from the literature or may be obtained by methods known from the literature.

The compounds of general formula I have useful biological properties. They are inhibitors of cholesterol biosynthesis, particularly inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase. In view of their biological properties they are particularly suitable for the treatment and prophylaxis of hyperlipidaemias, particularly hypercholesterolaemia, hyperlipoproteinaemia and hypertriglyceridaemia and the resulting atherosclerotic vascular changes with their sequelae such as coronary heart disease, cerebral ischaemia, Claudicatio intermittens, gangrene and the like.

In order to treat these diseases the compounds of general formula I may be used either on their own in monotherapy or in conjunction with other cholesterol- or lipid-lowering substances, the compounds preferably being given orally but optionally in rectal form. Drugs which may be used in conjunction with them include, for example:

- gallic acid binding resins such as cholestramine, cholestipol and the like, - compounds which inhibit cholesterol resorption such as sitosterol and neomycin, - compounds which are involved in cholesterol biosynthesis, e.g. HMG-CoA-reductase inhibitors such as lovastatin, simvastatin, pravastatin and the like, - squalene-epoxidase inhibitors such as NB 598 and analogous compounds and - squalene-synthetase inhibitors such as, for example, compounds of the category of the isoprenoid-(phosphinylmethyl)phosphonates and squalestatin.

Other possible combinations may include the fibrates such as clofibrate, bezafibrate, gemfibrozil and the like, nicotinic acid, the derivatives and analogues thereof such as acipimox and also probucol.

The compounds of general formula I are also suitable for treating diseases connected with excessive cell proliferation.
Cholesterol is an essential cell component and has to be present in sufficient quantities for cell proliferation, i.e.
cell division. The inhibition of cell proliferation by inhibiting cholesterol biosynthesis is described with reference to the example of the smooth muscle cells with the HMG-CoA-reductase inhibitor of the statin type, lovastatin, as mentioned hereinbefore.

Examples of diseases connected with excessive cell proliferation include in particular tumoral diseases. In cell culture and in vivo experiments it has been shown that a reduction of the serum cholesterol or intervention in cholesterol biosynthesis by HMG-CoA-reductase inhibitors reduces tumour growth (Lancet 339, 1154-1156 [1992]). The compounds of formula I according to the invention are therefore potentially suitable for treating tumoral diseases on the basis of their inhibitory effect on cholesterol biosynthesis. They may be used on their own or to support known types of therapy.

Other examples include hyperproliferative skin diseases such as psoriasis, basal cell carcinoma, plate epithelial carcinoma, keratosis and keratinisation disorders. The term "psoriasis" used here refers to a hyperproliferative skin disease which changes the regulating mechanism of the skin.
In particular, lesions are formed which constitute primary and secondary changes in proliferation in the epidermis, inflammatory skin reactions and the expression of regulatory molecules such as lymphokines and inflammatory factors.
Psoriatic skin is characterised morphologically by an increased turnover of epidermis cells, thickened epidermis, abnormal keratinisation of inflammatory skin infiltrates in the dermis and polymorphonuclear leukocyte infiltration into the epidermis, leading to an increase in the basal cell cycle.

21 ~8784 In addition, hyperkeratotic and parakeratotic cells are present. The terms "keratosis", "basal cell carcinoma", "plate epithelium carcinoma" and "keratinisation disorders'~
refer to hyperproliferative skin diseases in which the regulating mechanism for the proliferation and differentiation of the skin cells has been disrupted.

The compounds of formula I are effective as antagonists of skin hyperproliferation, i.e. as agents which inhibit the hyperproliferation of human keratinocytes. Consequently, they are suitable as agents for treating hyperproliferative skin diseases such as psoriasis, basal cell carcinoma, keratinisation disorders and keratosis. In order to treat these diseases the compounds of formula I may be administered either orally or topically, and may be used either on their own in form of monotherapy or in conjunction with known active substances.

Hyperproliferative vascular diseases such as stenosis and vascular occlusions based on the proliferation of smooth muscle cells, which are triggered by surgical procedures such as PT Q (percutaneous transll]m- n~ 1 coronary angioplasty) or bypass operations may also be mentioned. As stated hereinbefore, this cell proliferation can be suppressed, as is well known, by HMG-CoA-reductase inhibitors of the statin type such as lovastatin. On the basis of their inhibitory effect on cholesterol biosynthesis, the compounds of general formula I are suitable for treatment and prophylaxis of these diseases, and may be used either on their own or in conjunction with known active substances such as intravenously adminiRtered heparin, preferably in oral forms.

Another possible use of the compounds of general formula I
according to the invention is in the prevention and treatment of gallstone problems. The formation of gallstones is triggered by an unfavourable ratio of cholesterol to bile acid in the bile liquid, as a result of which the solubility of cholesterol is exceeded and cholesterol is precipitated in the form of gallstones. The effectiveness of the HMG-CoA-reductase inhibitor lovastatin in dissolving gallstones, particularly in conjunction with ursodeoxycholic acid, is described in Gastroenterology 102, No. 4, Pt.2, A319 [1992].
In view of their mode of activity the compounds of general formula I are therefore also important in the prevention and treatment of gallstone problems. They may be used either on their own or in conjunction with known therapies such as, for example, treatment with ursodeoxycholic acid or shockwave lithotripsy, and preferably administered orally.

Finally, the compounds of formula I are suitable for treating infections caused by pathogenic fungi such as Candida albicans, Aspergillus niger, Trichophyton mentagrophytes, Penicillium sp., Cladosporium sp. and others. As already mentioned above, the end product of sterol biosynthesis in the fungal organism is not cholesterol but ergosterol which is essential to the integrity and functioning of the fungal cell membranes. Inhibiting the biosynthesis of ergosterol therefore leads to disruption in growth and may possibly kill off the fungal organisms.

In order to treat mycoses the compounds of general formula I
may be administered either orally or topically. They may be used on their own or in conjunction with known antimycotic substances, particularly those which intervene in other stages of sterol biosynthesis, such as, for example, the squalene epoxidase inhibitors terbinafin and naftifin or the lanosterol-14a-demethylase inhibitors of the azole type such as ketoconazole and fluconazole.

Another possible use of the compounds of general formula I

21 887a4 concerns their use in poultry rearing. Lowering the cholesterol content of eggs by administering the HMG-CoA-reductase inhibitor lovastatin to laying hens has been described (FASEB Journal 4, A 533, Abstracts 1543 [1990]).
The production of low-cholesterol eggs is of importance since the cholesterol load in the body can be reduced by the use of eggs with a reduced cholesterol content without changing eating habits. In view of their inhibitory effect on cholesterol biosynthesis, the compounds of general formula I
may also be used in poultry rearing to produce low cholesterol eggs, the substances preferably being given as a feed additive.

The biological effect of compounds of general formula I was determined using the following methods:

I. Measuring the inhibition of l4C-acetate incorporation into the steroids which can be precipitated with digitonin:

Method:
Human hepatoma cells (HEP-G2) were grown for 3 days and then stimulated for 16 hours in cholesterol-free medium. The substances to be tested (dissolved in dimethylsulphoxide, final concentration 0.1~) were added during this stimulation phase. Then, after the addition of 200 ~Mol/l 2-l4C-acetate, incubation is continued for a further two hours at 37C in an incubator.

After the cells have been removed and the sterol esters have been saponified, digitonin is added after extraction and the sterols precipitated are isolated. The l4C-acetate incorporated in the sterols capable of being precipitated by digitonin is measured by scintillation counting.

The inhibitory effect was investigated at test concentrations of 10-7 mol/l and 10-8 mol/l. It was found that the following compounds A to Q of general formula I, for example, exhibited a good inhibitory effect at these test concentrations, e.g.
they showed an inhibitory effect of at least 50~ at a test concentration of 10-~ mol/l:

A = cis-0-(4-chlorobenzoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol B = cis-0-(4-phenyl-3-butenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol C = trans-0-(4-chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol D = cis-0-(5-methylhexanoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol E = trans-0-(2-phenylpropionyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol F = trans-0-(4-fluorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol G = trans-0-(3,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol H = cis-0-(4-fluoroclnn~moyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol I = trans-O-(p-tolylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol J = trans-0-(4-[trifluoromethyl]-phenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol 21 ~8784 K = trans-0-(2-naphthylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol L = trans-0-(4-nitrophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol M = trans-0-(4-bromophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol N = trans-0-(2,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol O = trans-0-([4-amino-3-chlorophenyl]acetyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol P = trans-0-(4-methoxyphenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol Q = trans-0-(4-chlorophenylacetyl)-4-(4-methylaminomethyl-phenyl)-cyclohexanol.

The percentages by which the above compounds inhibit 14C-acetate incorporation are given in the following Table:

21 88~84 mol/l 10-7 lo-8 As already mentioned, individual inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase have already been described in the literature but they are structurally very different from the compounds of formula I according to the invention.
The compounds which are most closely related in structure to the compounds of general formula I are described in EP 0 468 457. By way of a comparison, therefore, Example 1 of this publication was tested by the method described above in test concentrations of 10-5 mol/l and 10-6 mol/l. The inhibitory values of 41~ and 13~ obtained show that these compounds are significantly inferior to the compounds of general formula I according to the invention.

II. Measurement of the in vivo activity in the rat after oral administration Inhibition of the enzyme 2,3-epoxysqualene-lanosterol-cyclase brings about an increase in the 2,3-epoxysqualene levels in the liver and plasma. The quantity of 2,3-epoxysqualene formed therefore serves as a direct measurement of the potency on the animal as a whole. The measurement is carried out as follows:

Male Wistar rats (weighing 160-190 g) are given the substance, suspended in 1.5~ aqueous methyl cellulose, by oesphageal tube. 5 hours after administration, blood is taken retroorbitally from the venus plexus. Plasma is worked up using the method of Bligh and Dyer (Canad. J. Biochem.
Physiol. 37, 912, [1959]), purified using a preliminary column and then analysed with HPLC. The peaks obtained are identified and quantified using calibrating substances. An internal standard is used to test the reproducibility of the results.

The tests were carried out with concentrations of 0.1 and 1.0 mg/kg. In the Table which follows, the test data of the above-mentioned substances B, C, J, M, N and P are shown, by way of example, for the 2,3-epoxysqualene levels obtained in rat plasma. No measurable 2,3-epoxysqualene levels occur under the test conditions in the control animals.

2 3-F~oxysqualene levels in plasma (rat) 2,3-Epoxysqualene [~g/ml]
Substance 0.1 mg/kg 1.0 mg/kg B 0.4 1.1 C 0.6 4.2 J 0.5 3.6 M 0.6 3.5 N 0.1 2.2 P 0.3 0.9 None of the inhibitors of the enzyme 2,3-epoxysqualene-lanosterol-cyclase described in the literature has hitherto been found to inhibit cholesterol biosynthesis in the whole animal.

The compounds prove totally non-toxic at the curative dose.
For example, compound C shows no side effects in the rat, and compounds J and M show no side effects in the mouse, after oral administration of 100 mg/kg once a day for 5 days.

For pharmaceutical use the compounds of general formula I may be incorporated in the usual pharmaceutical preparations for oral and topical administration in a manner known per se.

Formulations for oral use include, for example, plain or coated tablets and capsules whilst suppositories are preferably used for rectal administration.

Topical formulations include gels, creams, lotions, ointments, powders, aerosols and other conventional preparations for using therapeutic agents on the skin. The quantity of active substance for topical use is 1 to 50 mg per gram of preparation but preferably 5 to 20 mg per gram of preparation.
As well as being used on the skin the topical formulations according to the invention may also be used in the treatment of mucosa which are accessible for topical treatment. For example, the topical formulations may be applied to the mucosa of the mouth, lower colon and elsewhere.

The oral or rectal daily dose is between 1 and 1200 mg for a person weighing 60 kg, but preferably the daily dose is from 5 to 100 mg for a person weighing 60 kg. The daily dose is preferably divided into 1 to 3 individual doses.

For topical use the compounds are administered in preparations containing about 1 to 1000 mg, more particularly 10 to 300 mg of active substance per day. The daily dose is preferably divided into 1 to 3 individual doses.

For use in poultry rearing in order to produce low cholesterol eggs, the active substances of general formula I are given to the animals in the form of an additive to their feed by normal methods. The concentration of active substances in the complete feed is normally 0.01 to 1~, but preferably 0.05 to 0.5%.

The active substances may be added to the feed as such. Thus, the feedstuffs according to the invention for laying hens will contain, apart from the active substance and possibly a conventional vitamin/mineral mixture, maize, soya flour, meatmeal, edible fat and soya oil, for example. One of the above-mentioned compounds of formula I is added to this feedstuff as an active substance in a concentration of 0.01 to 1~, but preferably 0.05 to 0.5~.

21 887~34 The Examples which follow are intended to illustrate the lnventlon:

In the following Examples the thin layer chromatography was carried out using ready-made TLC plates produced by Messrs.
E. Merck of Darmstadt, the plates being specifically:

a) silica gel 60 F254 b) aluminium oxide F2s4 (Type E) Preparation of the starting compounds Exam~le I

4-(4-Dimethylaminomethylphenyl)-cyclohexanone a) 4-(4-Dimethylaminomethylphenyl)-4-hydroxycyclohexanone-ethylene ketal To a solution of 36.4 g (0.17 mol) of 4-bromo-N,N-dimethylbenzylamine in 250 ml of dry tetrahydrofuran, cooled to -70C, are added dropwise, under a nitrogen atmosphere and with stirring, 112 ml (0.179 mol) of a 1.6 molar solution of n-butyllithium in hexane in such a way that the temperature does not exceed -65C. The orange solution is stirred for a further 15 minutes at -70C and then within 10 minutes a solution of 27.6 g (0.172 mol) of 1,4-cyclohexanedione-monoethylene ketal in 110 ml of tetrahydrofuran is added, whilst the temperature must not exceed -65C.

The reaction mixture is stirred first for 30 minutes at -70C
and then without external cooling until a temperature of +20C
is reached, then poured into 600 ml of ice water and extracted with 200 ml of ethyl acetate. The organic phase is separated off and the aqueous phase is extracted several times with ethyl acetate. The combined organic extracts are dried with sodium sulphate, evaporated down in vacuo and the residue rem~;n;ng is recrystallised from diisopropylether. 41.9 g (85% of theory) of 4-(4-dimethylaminomethylphenyl)-4-hydroxycyclohexanone-ethylene ketal are obtained, m.p.
84-86C.

b) 1-(4-Dimethylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexene A mixture of 22.4 g (0.077 mol) of 4-(4-dimethylaminomethyl-phenyl)-4-hydroxycyclohexanone-ethylene ketal, 15.0 g (0.079 mol) of p-toluenesulphonic acid monohydrate, 39 ml of ethylene glycol and 240 ml of toluene is refluxed for 3~ hours with stirring and the reaction water produced is continuously removed. The cooled reaction mixture is poured into 200 ml of water and adjusted to pH 12-13 with 2N NaOH. The organic phase is separated off and the aqueous phase is extracted several times with toluene. The combined organic extracts are dried with sodium sulphate and evaporated down in vacuo. 21 g (about 100~) of the title compound are obtained in the form of a yellow oil.

c) 1-(4-Dimethylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexane A solution of 21 g (0.077 mol) of crude 1-(4-dimethylamino-methyl)phenyl-4-ethylenedioxy-1-cyclohexene in 200 ml of ethyl acetate and 100 ml of methanol is combined with 5 g of palladium/barium sulphate catalyst and hydrogenated for 1.5 hours under a hydrogen pressure of 5 bar. After the catalyst has been removed the residue is evaporated down in vacuo.
20 g (about 100~) of the title compound are obtained as a yellowish-brown oil.

` - 2 1 88784 d) 4-(4-Dimethylaminomethyl)phenyl-cyclohexanone A mixture of 20 g (0.077 mol) of crude 1-(4-dimethylamino-methyl)phenyl-4-ethylenedioxy-1-cyclohexane and 110 ml of 2N
hydrochloric acid is stirred for 3.5 hours at ambient temperature. The aqueous solution formed is extracted several times with ethyl acetate; the organic extracts are discarded.
The aqueous phase is adjusted to pH 13-14 with 50~ sodium hydroxide solution whilst being cooled and is extracted several times with ethyl acetate. The combined organic extracts are washed with saturated sodium chloride solution, dried with sodium sulphate and evaporated down in vacuo. 14 g t79~ of theory) of 4-(4-dimethylaminomethyl)phenyl-cyclohexanone are obtained, melting point 64-67C, as a light yellow product. An analytical sample is recrystallised from petroleum ether 60/90.
Melting point: 65-67C
C1sH21NO (231.34) Calculated: C 77.88 H 9.15 N 6.05 Found: 77.69 9.32 5.98 Ex~le II

trans-4-(4-Dimethylaminomethylphenyl)-cyclohexanol To a solution of 11.1 g (0.048 mol) of 4-(4-dimethylaminomethylphenyl)-cyclohexanone in 100 ml of absolute methanol, which has been cooled to -10C, is added 1.82 g (0.048 mol) of sodium borohydride in batches with stirring.
The reaction mixture is allowed to react for 1.5 hours at ambient temperature and then evaporated down in vacuo. The residue remaining is mixed with water, acidified with concentrated hydrochloric acid, stirred for 30 minutes at ambient temperature, made alkaline with 50~ sodium hydroxide solution and extracted several times with chloroform. The ` - 21 887~4 combined extracts are dried with sodium sulphate and evaporated down in vacuo. The residue r~m~;n;~g, which consists of a mixture of trans/cis-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (cis fraction ~ 10~) is purified by column chromatography (aluminium oxide neutral, activity stage III, ICN; petroleum ether/methylethyl ketone = 5:1).
White crystals are obtained, melting point 63-65C.
Yield: 8.8 g (79~ of theory), l C1sH23NO (233.36) Calculated: C 77.21 H 9.93 N 6.00 Found: 77.34 10.02 5.89 Example III

cis-4-(4-Dimethylaminomethylphenyl)-cyclohexanol 50 ml (0.05 mol) of a 1 molar solution of lithium tri-sec.-butyl-borohydride in absolute tetrahydrofuran are diluted with 100 ml of absolute tetrahydrofuran under a nitrogen atmosphere and then, at -65C to -70C, with stirring and within 10 minutes, a solution of 5.8 g (0.025 mol) of 4-(4-dimethylaminomethylphenyl)-cyclohexanone in 50 ml of absolute tetrahydrofuran is added thereto. The reaction mixture is then left to react for 3 hours at -70C and then heated to ambient temperature within 1 hour. It is then hydrolysed with 20 ml of 75% aqueous ethanol and the organoborane is oxidised with alkaline hydrogen peroxide (10 ml of 6 M NaOH/15 ml 30~
H2O2). The organic phase is separated off, the aqueous phase is saturated with potassium carbonate and extracted with 50 ml of ethyl acetate. The combined organic extracts are dried with sodium sulphate and evaporated down in vacuo. The greasy residue r~;n;ng, which consists of a mixture of cis/trans-4-(4-dimethylaminomethylphenyl)cycloh~x~nol (trans fraction < 5~) is purified by column chromatography (aluminium oxide neutral, acti~ity stage III, ICN; petroleum ether/methylethyl 21 887~4 ketone = 5:1).
The product is obtained as a colourless oil.
Yield: 4.1 g (71~ of theory).
1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.5-2.0 (2m,8H); 2.25 (s,6H); 2.4-2.65 (m,lH); 3.4 (s,2H);
4.1-4.18 (m,lH); 7.15-7.3 (m,4H).

Example IV

trans-O-Acetyl-4-(4-chloromethylphenyl)-cyclohexanol a) 4-Phenylcyclohexanol To a solution of 31.4 g (0.18 mol) of 4-phenylcyclohexanone in 500 ml of absolute methanol, which is cooled to -10C, are added 6.8 g (0.18 mol) of sodium borohydride in batches with stirring. The reaction mixture is allowed to react for 0.5 hours at -10C and for 3 hours at ambient temperature and then evaporated down in vacuo. The residue remaining is mixed with water and acidified with 2N hydrochloric acid. The suspension formed is stirred for 1 hour and the crystalline product is suction filtered, dried and recrystallised from diisopropylether. 21 g (66~ of theory) of 4-phenylcyclohexanol are obtained, melting point: 112-114C.

b) O-Acetyl-4-phenylcyclohexanol To a mixture of 20.3 g (0.115 mol) of 4-phenylcyclohexanol, 14.2 ml (0.15 mol) of acetanhydride and 29 ml of triethylamine are added, with stirring and at ambient temperature, 2.3 g (0.02 mol) of 4-dimethylaminopyridine, a clear solution being produced in an exothermic reaction. This is heated to 80C
for 3 hours and the reaction mixture is then poured into ice water. The crystalline product precipitated is suction filtered, dissolved in ether, washed with sodium bicarbonate ` - 21 88784 solution, dried and evaporated down in vacuo. 23 g (92% of theory) of O-acetyl-4-phenylcyclohexanol are obtained. The product is obtained initially as an oil but crystallises when left to stand.
Melting point: 43-45C.

c) trans-O-Acetyl-4-(4-chloromethylphenyl)-cyclohexanol 7 A solution of 24.3 g (0.11 mol) of O-acetyl-4-phenylcyclohexanol in 1300 ml of methylene chloride is combined with 26.0 g (0.86 mol) of paraformaldehyde and 26.0 g (o.l9 mol) of zinc chloride. Hydrogen chloride is introduced into this suspension, with stirring, for 2.5 hours, whilst the temperature rises to about 30C and a substantially homogeneous solution is formed. The mixture is then allowed to react for 15 hours at ambient temperature and the reaction mixture is then hydrolysed with stirring in about 1.5 litres of ice water. The organic phase is separated off, the aqueous phase is extracted with methylene chloride again and the two organic phases are combined. They are washed until neutral, dried and evaporated in vacuo. The yellow oil rem~;n;ng is crystallised by trituration with diisopropylether and the solid product is recrystallised from diisopropylether. White crystals are obtained, melting point 87-89C.
Yield: 12.7 g (43% of theory).
Cl5H1gClO2 (266.77) Calculated: C 67.53 H 7.18 Cl 13.29 Found: 67.68 7.29 13.11 2l ~8184 Exam~le V

cis/trans-O-(4-Chlorophenylacetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol a) 4-(4-Methylaminomethyl)phenyl-4-hydroxycyclohexanone-ethylene ketal A solution of 94 g (0.47 mol) of 4-bromo-(N-methyl)-benzylamine in 460 ml of dry tetrahydrofuran is combined first with 300 ml (0.48 mol) of a 1.6 molar solution of n-butyl lithium in hexane and then with 52.5 g (0.48 mol) of trimethylchlorosilane, under a nitrogen atmosphere and at -30 to -25C. The reaction mixture is stirred for a further 15 minutes at this temperature and then cooled to -75~C. Then another 320 ml (0.51 mol) of a 1.6 molar solution of n-butyllithium in hexane are added so that the temperature does not exceed -70C. The mixture is stirred for a further 20 minutes at -75C and then, within 20 minutes, mixed with a solution of 76 g (0.47 mol) of 1,4-cyclohexanedione-monoethylene ketal in 200 ml of tetrahydrofuran, whilst the temperature should not exceed -65C. The reaction mixture is then stirred first for 30 minutes at -70C and then without external cooling until a temperature of +20C is reached. It is then decomposed in ice cold aqueous ammonium chloride solution and extracted several times with methylene chloride.
The combined organic extracts are dried with sodium sulphate, the solvent is eliminated and the residue rem~1n1ng is recrystallised from diisopropylether. 77 g (59~ of theory) of 4-(4-methylaminomethyl)phenyl-4-hydroxycyclohexanone-ethylene ketal are obtained, melting point 95-97C.

b) 1-(4-Methylaminomethyl)phenyl-4-ethylenedioxy-1-cylohexene A mixture of 68 g (0.24 mol) of 4-(4-methylaminomethyl)-` ~188784 phenyl-4-hydroxycyclohexanone-ethylene ketal, 51 g (0.27 mol) of p-toluenesulphonic acid monohydrate, 150 ml of ethylene glycol and 900 ml of toluene is refluxed for 2.5 hours with stirring and the reaction water formed is continuously removed. The cooled reaction mixture is made alkaline with lN
sodium hydroxide solution (pH 12-13), the organic phase is separated off and the aqueous phase is extracted several times with ethyl acetate. The combined organic phases are dried with sodium sulphate and evaporated down in vacuo. 63 g (about 100~ of theory) of 1-(4-methylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexene are obtained as a yellowish oil.

c) 1-(4-N-[tert.-Butoxycarbonyl]-methylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexene A solution of 63 g (0.24 mol) of the crude 1-(4-methylamino-methyl)phenyl-4-ethylenedioxy-1-cyclohexene in 350 ml of absolute tetrahydrofuran is combined, with stirring, with a solution of 58 g (0.26 mol) of di-tert.-butyldicarbonate in 100 ml of absolute tetrahydrofuran, the temperature being maintained at between 15 and 20C by cooling. After the development of CO2 has died away, the mixture is left for a further 10 hours at ambient temperature, the solvent is distilled off in vacuo, the residue is mixed with water and extracted several times with ether. After drying with sodium sulphate and evaporation 84 g (about 100~ of theory) of 1-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexene are obtained as a yellowish oil.

d) 4-(4-N-[tert.-Butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanone A solution of 84 g (0.24 mol) of the crude 1-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-4-ethylenedioxy-1-cyclohexene in methanol/ethyl acetate (250+250 ml) is combined with 10 g of palladium/barium sulphate catalyst and hydrogenated for 4 hours at ambient temperature under a hydrogen pressure of 3 bar. The catalyst is separated off, the solvent is distilled off in vacuo, the oily residue is dissolved in acetone/water (1400+140 ml), and after the addition of 8.5 g (0.034 mol) of pyridinium tosylate, it is refluxed for 15 hours. The solvent is then distilled off in vacuo, the residue is combined with water and extracted several times with methylene chloride. After the organic phase has been dried with sodium sulphate and evaporated down, 61 g (77~ of theory) of 4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanone are obtained as a pale yellow oil which solidifies when left to stand for a length of time.
Melting point: 55-57C.

e) 4-(4-N-[tert.-Butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) 1.31 g (0.035 mol) of sodium borohydride is added in batches, with stirring, to a solution of 11 g (0.035 mol) of 4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanone in 70 ml of absolute methanol, cooled to -10C. The reaction mixture is allowed to react for 0.5 hours at -10C and for 2 hours at ambient temperature and then evaporated down in vacuo. The residue rem~;n;ng is mixed with water and stirred for 1 hour at ambient temperature. The solid product produced is suction filtered, dissolved in ethyl acetate and this solution is dried over sodium sulphate. After evaporation in vacuo, 8.6 g (77~ of theory) of a mixture of the cis- and trans-forms of 4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol are left in the form of a colourless oil. This can be separated into the pure isomers by column chromatography (aluminium oxide neutral, activity stage III, ICN; petroleum ether/ethyl acetate = 3:1).

Rf value (aluminium oxide; petroleum ether/ethyl acetate =
3:1): 0.21 (trans) and 0.31 (cis).

f) 0-(4-Chlorophenylacetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) A mixture of 0.54 g (0.0032 mol) of 4-chlorophenylacetic acid, 0.52 g (0.0032 mol) of N,N'-carbonyldiimidazole and 20 ml of xylene is heated to 60C for 1 hour with stirring. Then a solution of 0.85 g (0.0027 mol) of 4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) in 10 ml of xylene is added and the reaction mixture is heated to 160C for a further 8 hours.
After cooling, it is evaporated down in vacuo, the residue is mixed with water and extracted with ethyl acetate. The organic phase is dried over sodium sulphate and evaporated down in vacuo. 1. 3 g (about 100% of theory) of 0-(4-chlorophenylacetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) are left as a reddish-brown oil.
Rf value (aluminium oxide; petroleum ether/ethyl acetate =
3:1): 0.78 (trans) and 0.85 (cis).

The following substance was synthesised analogously:

(1) trans-O-(4-chlorophenylacetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohex~nol from trans-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)-phenyl-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 94-96C.

2 1 887~4 Preparat;on of the end products:

~xample 1 trans-O-(4-Chlorobenzoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol A solution of 1.0 g (0.0043 mol) of trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 0.6 ml of triethylamine in 50 ml of methylene chloride is combined, dropwise, with 0.75 g (0.0043 mol) of 4-chlorobenzoylchloride, with stirring, and refluxed for 3 hours. After cooling, 50 ml of water are added, the mixture is adjusted to pH 12-13 with sodium hydroxide solution, the methylene chloride phase is separated off and the aqueous phase is extracted once more with methylene chloride. The combined organic phases are dried over sodium sulphate and evaporated down in vacuo. The solid residue is purified by column chromatography (aluminium oxide neutral, activity stage III, ICN; petroleum ether/ethyl acetate = 40:1). White crystals are obtained with a melting point of 94-95C.
Yield: 1.1 g (69~ of theory) lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.55-1.8 (m,4H); 1.9-2.1 (m,2H); 2.15-2.3 (s+m,6+2H); 2.5-2.7 (m,lH); 3.4 (s,2H); 4.9-5.1 (m,lH); 7.15-7.3 (m,4H); 7.4 (d,2H); 8.0 (d,2H).

The following substances were synthesised analogously:

(1) trans-O-acetyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and acetylchloride/triethylamine.

21 ~8784 Colourless syrup.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.45-1.7 (m,4H); 1.9-2.05 (m,2H); 2.05-2.15 (s+m,3+2H); 2.23 (s,6H); 2.4-2.65 (m,lH); 3.4 (s,2H); 4.7-4.9 (m,lH); 7.1-7.3 (m,4H).

(2) trans-O-butyryl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and butyric acid chloride/triethylamine.
Colourless oil.
lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:
0.9-1.02 (t,3H); 1.45-1.75 (m,6H); 1.89-2.05 (m,2H); 2.05-2.18 (m,2H); 2.18-2.38 (s+t,6+2H); 2.4-2.6 (m,lH); 3.4 (s,2H);
4.7-4.9 (m,lH); 7.1-7.3 (m,4H).

~3) trans-O-cyclopropanoyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and cyclopropane carboxylic acid chloride/triethylamine.
Colourless wax.
lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:
0.81-0.87 (m,2H); 0.95-1.02 (m,2H); 1.45-1.7 (m,4H); 1.9-2.0 (m,2H); 2.05-2.15 (m,2H); 2.24 (s,6H); 2.4-2.63 (2m,2H); 3.4 (s,2H); 4.73-4.83 (m,lH); 7.12-7.25 (m,4H).

(4) trans-O-cyclohexanoyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from tran~-4-(4-dimethylaminomethylphenyl)-cyclohexanol and cyclohexane carboxylic acid chloride/triethylamine.
White crystals.
Melting point: 66-68C.

(5) cis-O-(4-chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-chlorophenylacetylchloride/triethylamine.
Colourless oil.
lH-NMR spectrum (200 MHz, CDC13); signals at ppm:
1.5-1.75 (m,6H); 1.88-2.05 (m,2H); 2.25 (s,6H); 2.4-2.65 (m,lH); 3.4 (s,2H); 3.65 (s,2H); 5.05-5.15 (m,lH); 7.08 (d,2H), 7.2-7.4 (m,6H).

(6) trans-O-(4-phenyl-3-butenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-phenyl-3-butenoic acid chloride/triethylamine.
White crystals.
Melting point: 90-91C.

(7) cis-O-(4-phenyl-3-butenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-phenyl-3-butenoic acid chloride/triethylamine.
White crystals.
Melting point: 71-73C.

Ex~m~le 2 trans-O-(4-Chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol To a mixture of 0.43 g (0.0025 Mol) of 4-chlorophenylacetic acid and 30 ml of xylene are added 0.41 g (0.0025 Mol) of N,N'-carbonyldiimidazole, a white product being produced with the release of CO2. The reaction mixture is heated to 60C for 1 hour with stirring and then 0.5 g (0.0021 mol) of trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol are added. The mixture is heated to 160C for 12 hours with stirring, cooled to ambient temperature, mixed with water and adjusted to pH
12-13 using 2N sodium hydroxide solution. The xylene phase is separated off, the aqueous phase is extracted several times with ethyl acetate, the organic phases are combined, dried and evaporated down in vacuo. The solid residue is purified by column chromatography (aluminium oxide basic, activity stage III, ICN; petroleum ether/ethyl acetate = 10:1). White crystals are obtained with a melting point of 75-77C.
Yield: 0.7 g (86~ of theory).
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.7 (m,4H); 1.8-2.15 (m,4H); 2.25 (s,6H); 2.4-2.6 (m,lH);
3.38 (s,2H); 3.6 (s,2H); 4.7-4.9 (m,lH); 7.1-7.35 (m,8H).

The following substances were synthesised analogously:

(1) trans-O-(5-methylhexanoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 5-methylhexanoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 35-36C.

(2) cis-O-(5-methylhexanoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohex~nol from cis-4-(4-dimethylaminomethylphenyl)-cycloh~nol and 5-methylhexanoic acid/N,N'-carbonyldiimidazole.
Colourless oil.
lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:

0.9 (d,6H); 1.15-1.32 (m,2H); 1.5-1.88 (m,9H); 1.95-2.1 (m,2H); 2.25 (s,6H); 2.3 (d,2H); 2.48-2.69 (m,lH); 3.4 (s,2H);
5.08-5.18 (m,lH); 7.12-7.3 (m,4H).

(3) trans-O-cyclohexylacetyl-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and cyclohexylacetic acid/N,N'-carbonyldiimidazole White crystals.
Melting point: 37-39C.

(4) trans-O-(2-butenoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and crotonic acid/N,N'-carbonyldiimidazole White crystals.
Melting point: 69-71C.

(5) trans-O-(2-hexenoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-hexenoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 40-42C.

(6) trans-O-(3-cyclohexylpropenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3-cyclohexylpropenoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 46-47C.

(7) trans-O-benzoyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and benzoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 68-70C.

(8) trans-O-(4-chloro-3-methylbenzoyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-chloro-3-methylbenzoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 100-102C.

(9) trans-O-(2-naphthoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-naphthoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 110-112C.

(10) trans-O-phenylacetyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and phenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 38-40C.

(11) trans-O-(4-fluorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol 2 1 ~878~

from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-fluorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 68-70C.

(12) cis-O-(4-fluorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-fluorophenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.5-1.75 (m,6H); 1.85-2.05 (m,2H); 2.3 (s,6H); 2.4-2.65 (m,lH); 3.43 (s,2H); 3.65 (s,2H); 5.05-5.15 (m,lH); 7.0-7.15 (m,4H); 7.2-7.38 (m,4H).

(13) trans-O-(4-bromophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-bromophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 72-74C.

(14) trans-O-(3,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3,4-dichlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 95-97C.

(15) cis-O-(3,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3,4-dichlorophenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.5-1.75 (m,6H); 1.9-2.05 (m,2H); 2.28 (s,6H); 2.4-2.65 (m,lH); 3.4 (s,2H); 3.62 (s,2H); 5.8-5.17 (m,lH); 7.05-7.3 (m,5H); 7.35-7.49 (m,2H).

(16J trans-O-(2,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2,4-dichlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 78-80C.

(17) trans-O-(p-tolylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and p-tolylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 40-42C.

(18) trans-O-(4-[trifluoromethyl]-phenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-(trifluoromethyl)-phenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 73-75C.
(19) trans-O-(4-methoxyphenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-methoxyphenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 47-49C.
(20) trans-O-(4-nitrophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-nitrophenylacetic acid/N,N'-carbonyldiimidazole.
Yellowish crystals.
Melting point: 136-137C.
(21) trans-O-[3-(4-fluorophenyl)-propionyl]-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3-(4-fluorophenyl)-propionic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 58-59C.
(22) trans-O-[3-(4-chlorophenyl)-propionyl]-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3-(4-chlorophenyl)-propionic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 85-87C.
(23) trans-O-(4-biphenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-biphenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.

Melting point: 88-89C.
(24) trans-0-(2-naphthylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-naphthylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 85-87~.
(25) trans-O-[2-(1,2,3,4-tetrahydro)naphthoyl]-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-(1,2,3,4-tetrahydro)naphthoic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 95-96~.
(26) cis-0-[2-(1,2,3,4-tetrahydro)naphthoyl]-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-(1,2,3,4-tetrahydro)naphthoic acid/N,N'-carbonyldiimidazole.
Colourless oil.
1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.55-1.85 (m,6H); 1.9-2.1 (m,3H); 2.15-2.32 (s+m,6+1H)i 2.4-2.65 (m,lH); 2.72-2.95 (m,3H); 3.05 (d,2H); 3.4 (s,2H);
5.1-5.2 (m,lH); 7.05-7.3 (2m,8H).
(27) trans-O-(2-phenylpropionyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-phenylpropionic acid/N,N'-carbonyldiimidazole.
Colourless wax.

~1 887~

1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.25-1.7 (d+m,3+3H); 1.8-2.15 (m,5H); 2.3 (s,6H); 2.38-2.6 (m,lH); 3.4 (s,2H); 3.7 (q,lH); 4.68-4.9 (m,lH); 7.15 (d,2H);
7.18-7.38 (d+m,2+5H).
(28) cis-O-(2-phenylpropionyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-phenylpropionic acid/N,N'-carbonyldiimidazole.
Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.3-1.7 (d+m,3+6H); 1.8-2.05 (m,2H); 2.25 (s,6H); 2.35-2.58 (m,lH); 3.4 (s,2H); 3.78 (q,lH); 5.0-5.1 (m,lH); 7.0 (d,2H);
7.2 (d,2H); 7.25-7.4 (m,5H).
(29) trans-O-(4-fluorocinnamoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-fluoroc'nn~mic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 118-120C.
(30) cis-O-(4-fluoroc;nn~moyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-fluorocinnamic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 66-68C.
(31) trans-0-(4-chloroclnn~moyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol ~1 8~784 from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-chlorocinnamic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 131-133C.
(32) cis-0-(4-chloroc;nn~mQyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-chloroc;nn~m;c acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 88-90C.
(33) trans-0-(4-[trifluoromethyl]-cinnamoyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-(trifluoromethyl)-c; nn~m; C acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 134-136C.
(34) cis-0-(4-[trifluoromethyl]-c;nn~moyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-(trifluoromethyl)-c;nn~m;c acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 61-63C.
(35) trans-0-(5-chloro-2-thenoyl]-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 5-chloro-2-thiophenecarboxylic acid/N,N'-carbonyldiimidazole.
White crystals.

Melting point: 95-97C.
(36) trans-O-nicotinoyl-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and nicotinic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 86-88C.
(37) trans-O-(2-furoyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 2-furancarboxylic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 58-60C.
(38) trans-O-(3,4-dimethoxyphenylacetyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3,4-dimethoxyphenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 32-34C.
(39) trans-O-(4-amino-3-chlorophenylacetyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-amino-3-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 83-85C.
(40) trans-0-(4-amino-3,5-dichlorophenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 4-amino-3,5-dichlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 78-80C.
(41) trans-O-(4-chlorophenylacetyl)-4-(4-diethylaminomethyl phenyl)-cyclohexanol ;

from trans-4-(4-diethylaminomethylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
lH-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.05 (t,6H); 1.4-1.72 (m,4H); 1.9-2.2 (m,4H); 2.4-2.6 (q+m,5H); 3.5 (s,2H); 3.6 (s,2H); 4.7-4.9 (m,lH); 7.12 (d,2H);
7.18-7.35 (m,6H).
(42) trans-O-(4-chlorophenylacetyl)-4-(4-dipropylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-dipropylaminomethylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
0.88 (t,6H); 1.38-1.7 (m,8H); 1.9-2.19 (m,4H); 2.35 (q,4H);
2.4-2.6 (m,lH); 3.5 (s,2H); 3.6 (s,2H); 4.7-4.9 (m,lH); 7.1 (d,2H); 7.15-7.38 (m,6H).
(43) trans-O-(4-chlorophenylacetyl)-4-(4-[N-methylbutylamino]methylphenyl)-cyclohexanol from trans-4-(4-[N-methylbutylamino]-methylphenyl)-cyclohe~nol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.

~1 ~878~

Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
o.9 (t,3H); 1.2-1.7 (m,8H); 1.8-2.15 (m,4H); 2.18 (s,3H); 2.35 (t,2H); 2.4-2.6 (m,lH); 3.41 (s,2H); 3.6 (s,2H); 4.7-4.9 (m,lH); 7.1 (d,2H); 7.2-7.35 (m,6H).
(44) trans-O-(4-chlorophenylacetyl)-4-(4-diallylaminomethyl-phenyl)-cyclohexanol from trans-4-(4-diallylaminomethylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.75 (m,4H); 1.9-2.2 (m,4H); 2.4-2.6 (m,lH); 3.0-3.18 (dd,4H); 3.5 (s,2H); 3.6 (s,2H); 4.7-4.9 (m,lH); 5.1-5.3 (m,4H); 5.75-6.0 (m,2H); 7.12 (d,2H); 7.15-7.38 (m,6H).
(45) trans-O-(4-chlorophenylacetyl)-4-(4-[N-pyrrolidino]-methylphenyl)-cyclohexanol from trans-4-(4-[N-pyrrolidino]methylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 57-59C.
(46) trans-O-(4-chlorophenylacetyl)-4-(4-[N-piperidino]-methylphenyl)-cyclohexanol from trans-4-(4-[N-piperidino]methylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 87-89C.
(47) trans-O-(4-chlorophenylacetyl)-4-(4-[N-morpholino]-methylphenyl)-cyclohexanol 21 8~784 from trans-4-(4-[N-morpholino]methylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 114-116C.
(48) trans-O-(4-chlorophenylacetyl)-4-(4-[N-methyl-N'-piperazino]methylphenyl)-cyclohexanol ~1 from trans-4-(4-[N-methyl-N'-piperazino]methylphenyl)-cyclohexanol and 4-chlorophenylacetic acid/N,N'-carbonyldiimidazole.
White crystals.
Melting point: 97-99C.
(49) trans-O-(3,4-[methylenedioxy]-phenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol from trans-4-(4-dimethylaminomethylphenyl)-cyclohexanol and 3,4-(methylenedioxy)-phenylacetic acid/N,N'-carbonyldiimidazole.
Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.7 (m,4H), 1.8-2.0 (m,2H), 2.0-2.15 (m,2H), 2.25 (s,6H), 2.4-2.6 (m,lH), 3.38 (s,2H), 3.5 (s,2H), 4.7-4.9 (m,lH), 5.94 (s,2H), 6.7-6.85 (m,3H), 7.1-7.3 (m,4H).

Ex~m~le 3 cis-O-(4-Chlorobenzoyl)-4-(4-dimethylaminomethylphenyl~-cyclohexanol 0.24 g (0.001 mol) of cis-4-(4-dimethylaminomethylphenyl)-cyclohexanol, 0.34 ml (0.0025 mol) of triethylamine and 0.12 g (0.001 mol) of dimethylaminopyridine are dissolved in 20 ml of methylene chloride, mixed with 0.175 g (0.001 mol) of 4-chlorobenzoylchloride and stirred for 12 hours at ambient temperature. The reaction mixture is combined with water and adjusted to pH 12-13 using sodium hydroxide solution. The methylene chloride phase is separated off, the aqueous phase is extracted several times with methylene chloride and the combined organic phases are washed with saturated saline solution, dried and evaporated down in vacuo. The residue is purified by column chromatography (aluminium oxide neutral, activity stage III, ICN; petroleum ether/ethyl acetate = 45:1) White crystals.
Melting point: 96-97C.
Yield: 0.27 g (73~ of theory) H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.7-2.0 (m,6H); 2.1-2.25 (m,2H); 2.28 (s,6H); 2.55-2.75 (m,lH); 3.4 (s,2H); 5.33-5.4 (m,lH); 7.15-7.3 tm,4H)i 7-45 (d,2H); 8.2 (d,2H).

Ex~m~le 4 trans-O-Acetyl-4-(4-diethylaminomethylphenyl)-cyclohexanol A solution of 1 g (3.75 mmol) of trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol in 10 ml of dimethylformamide is mixed with 0.52 g (3.75 mmol) of potassium carbonate and 0.27 g (3.75 mmol) of diethylamine. This mixture is heated to 21 8~784 50C for 6 hours with stirring, then water is added and the mixture is extracted with methylene chloride. The organic phase is dried, evaporated down in vacuo and the residue rem~;ni~g is purified by column chromatography (aluminium oxide basic, activity stage III, ICN; petroleum ether/ethyl acetate = 15:1).
Colourless oil.
Yield: 0.79 g (69~ of theory) 1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.05 (t,6H); 1.45-1.75 (m,4H); 1.9-2.2 (s+m,7H); 2.4-2.6 (q+m,5H); 3.55 (s,2H); 4.68-4.9 (m,lH); 7.12 (d,2H); 7.28 (d,2H).

The following substances were synthesised analogously:

(1) trans-O-acetyl-4-(4-dipropylaminomethylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and dipropylamine.
Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
0.9 (t,6H); 1.35-1.75 (m,8H); 1.9-2.2 (s+m,7H); 2.3-2.6 (q+m,5H); 3.5 (s,2H); 4.65-4.9 (m,lH); 7.1 (d,2H); 7.25 (d,2H).

(2) trans-O-acetyl-4-(4-[N-methylbutylamino]-methylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and N-methylbutylamine.
Colourless oil.
1H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
0.9 (t,3H); 1.2-1.75 (m,lOH); 1.9-2.2 (2s+m,8H); 2.38 (t,2H);
2.4-2.6 (m,lH); 3.45 (s,2H); 4.7-4.9 (m,lH); 7.15 (d,2H); 7.25 ~1 88~4 (d,2H).

(3) trans-O-acetyl-4-(4-diallylaminomethylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and diallylamine.
Colourless oil.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.7 (m,4H); 1.9-2.18 (s+m,7H); 2.4-2.6 (m,lH); 3.09 (dd,4H); 3.52 (s,2H); 4.7-4.9 (m,lH); 5.01-5.3 (m,4H);
5.75-6.0 (m,2H); 7.12 (d,2H); 7.35 (d,2H).

(4) trans-O-acetyl-4-(4-[N-pyrrolidino]methylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and pyrrolidine.
Colourless crystals.
Melting point: 43-45C.

(5) trans-O-acetyl-4-(4-[N-morpholino]methylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and morpholine.
Colourless crystals.
Melting point: 53-55C.

(6) trans-O-acetyl-4-(4-[N-piperidino]methylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and .
plperldlne.
Colourless crystals.

21 8~78~

Melting point: 62-64C.

(7) trans-O-acetyl-4-[N-methyl-N'-piperazino]methylphenyl)-cyclohexanol from trans-O-acetyl-4-(4-chloromethylphenyl)-cyclohexanol and N-methylpiperazine.
Colourless crystals.
Melting point: 50-52C.

~xam~le 5 trans-0-(4-Chlorophenylacetyl)-4-(4-methylaminomethylphenyl)-cyclohexanol A solution of 8.9 g (0.019 Mol) of trans-O-(4-chlorophenyl-acetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)-phenyl-cyclohexanol in 200 ml of methylene chloride is combined with 35 ml of trifluoroacetic acid and stirred for 2 hours at ambient temperature. Then the volatile components are distilled off in vacuo, the residue is taken up in methylene chloride and washed to neutral with saturated sodium hydrogen carbonate solution. The organic phase is dried over sodium sulphate and evaporated down in vacuo. A yellowish oil rem~; ns which is purified by column chromatography (aluminium oxide basic, activity stage III, ICN; petroleum ether/ethyl acetate/methanol = 10:10:1). Yellowish white crystals are obtained, melting point 65-67C.
Yield: 6.4 g (91~ of theory).
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.7 (m,4H); 1.8-2.0 (m,2H), 2.0-2.2 (m,2H), 2.4-2.6 (s+m,3+1H), 3.58 (s,2H), 3.7 (s,2H); 4.7-4.9 (m,lH), 7.1-7.35 (m,8H).

The following substance was synthesised analogously:

(1) 0-(4-chlorophenylacetyl)-4-(4-methylaminomethylphenyl)-cyclohexanol (cis/trans mixture) from 0-(4-chlorophenylacetyl)-4-(4-N-[tert.-butoxycarbonyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) and trifluoroacetic acid.
Yellow oil.
Rf value (aluminium oxide; petroleum ether/ethyl acetate/methanol = 10:10:1): 0.28-0.53.

Example 6 O-(4-Chlorophenylacetyl)-4-(4-N-[carboxamidomethyl]-methylaminomethyl)phenyl-cyclohexanol (cis/trans mixture) A mixture of 1.0 g (0.0027 mol) of 0-(4-chlorophenylacetyl)-4-(4-methylaminomethylphenyl)-cyclohexanol (cis/trans mixture), 0.5 g (0.0027 mol) of iodoacetamide, 0.37 g (0.0027 mol) of potassium carbonate and 5 ml of dimethylformamide is heated to 50C for 2 hours with stirring. After it has cooled to ambient temperature, water is added and the mixture is extracted with ethyl acetate. The organic phase is dried over sodium sulphate, the volatile components are distilled off in vacuo and the residue is purified by column chromatography (aluminium oxide basic, activity stage III, ICN; petroleum ether/ethyl acetate/methanol = 60:40:2.5).
A white crystalline product is obtained which sinters from 110C and melts between 128-132~C.
H-NMR spectrum (200 MHz, CDCl3); signals at ppm:
1.4-1.75 (m,5H); 1.8-2.2 (m,3H), 2.32 (dd,3H), 2.4-2.63 (m,lH), 3.0 (dd,2H), 3.5-3.7 (dd+dd,2+2H), 4.7-4.9 (m,0.5H), 5.08-5.15 (m,0.5H), 7.0-7.4 (m,8H).

21 887&4 The following substances were synthesised analogously:

(1) trans-O-(4-chlorophenylacetyl)-4-(4-N-[carbethoxymethyl]-methylaminomethyl)phenyl-cyclohexanol from trans-O-(4-chlorophenylacetyl)-4-(4-methylaminomethyl-phenyl)-cyclohexanol, ethylbromoacetate and potassium carbonate/dimethylformamide.
White solid product.
Melting point: 40-42C.

(2) trans-O-(4-chlorophenylacetyl)-4-(4-N-[3-hydroxypropyl]-methylaminomethyl)phenyl-cyclohexanol from trans-O-(4-(chlorophenylacetyl)-4-(4-methylaminomethyl-phenyl)-cyclohexanol, 3-bromopropanol and potassium carbonate/dimethylformamide.
White crystals.
Melting point: 75-77C.

Ex~m~le 7 trans-O-(4-Chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol-hydrochloride A solution of 0.39 g (0.001 mol) of trans-O-(4-chlorophenyl-acetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol in 10 ml of diethyl ether is combined at ambient temperature, with stirring, with a 1.5 times equimolar amount of hydrogen chloride in isopropanol added dropwise. The precipitate formed is left for 1 hour at ambient temperature, suction filtered, washed repeatedly with diethyl ether and dried.
White crystals are obtained, melting point 231-233C.
Yield: 0.32 g (76% of theory).

21~78~

C23H29Cl2NO2 (422.40) Calculated: C 65.40 H 6.92 N 3.32 Cl 16.79 Found: 65.33 7.06 3.45 16.92 Exam~1e 8 trans-O-(4-Chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol-tartrate First 0.15 g (0.001 mol) of anhydrous tartaric acid and then 0.39 g (0.001 mol) of trans-O-(4-chlorophenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol are dissolved in 7 ml of absolute ethanol. Diethyl ether is then added to the clear solution until it becomes slightly cloudy and it is then left to stand for 8 hours at +4C. The crystalline product precipitated is suction filtered, washed with diethyl ether and dried.
Melting point: 169-171C.
Yield: 0.46 g (86~ of theory).
C27H34ClNO8 (536.02) Calculated: C 60.50 H 6.39 N 2.61 Cl 6.61 Found: 60.37 6.38 2.65 6.73 2 1 887~34 The following Examples illustrate the preparation of some pharmaceutical administration forms:

F.~m~le I

Tablets containing 5 mg of trans-O-(4-chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol Composition:
1 tablet contains:
Active substance 5.0 mg Lactose 148.0 mg Potato starch 65.0 mg Magnesium stearate 2.0 mg 220.0 mg Method of preparat;on A 10~ mucilage is prepared from potato starch by heating. The active substance, lactose and the rem~;n;ng potato starch are mixed together and granulated with the above mucilage through a 1.5 mm mesh screen. The granules are dried at 45C, rubbed through the same screen again, mixed with magnesium stearate and compressed to form tablets.
Weight of tablet: 220 mg Punch: 9 mm 2 1 887~4 Example II

Coated tablets containing 5 mg of trans-O-(4-chlorophenyl-acetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol The tablets prepared according to Example I are coated, by a known method, with a coating consisting essentially of sugar and talc. The finished coated tablets are polished with beeswax.
Weight of coated tablet: 300 mg Example III

Suppositories containing 5 mg of trans-O-(4-chlorophenyl-acetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol Composition:
1 suppository contains:
Active substance 5.0 mg Suppository mass (e.g. Witepsol W 45~)1 695.0 m~
1 700.0 mg Method of prep~rat~on:

The finely powdered active substance is suspended in the molten suppository mass which has been cooled to 40C. At 37C
the mass is poured into slightly chilled suppository moulds.
Weight of suppository 1.7 g ` 21 88784 ~m~le IV

Capsules containing 5 mg of trans-O-(4-[trifluoromethyl]-phenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol Composition:
1 capsule contains:
Active substance 5.0 mg Lactose 82.0 mg Starch 82.0 mg Magnesium stearate 1.0 mg 170.0 mg Method of preparation:

The powder mixture is mixed thoroughly and packed into size 3 hard gelatine capsules in a capsule filling machine, the end weight being continuously monitored.

~x~m~le V

Tablets containing 5 mg of trans-O-(4-bromophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol Composition:
1 tablet contains:
Active substance 5.0 mg Lactose 148.0 mg Potato starch 65.0 mg Magnesium stearate 2.0 mg 220.0 mg `- 21 88784 Method of preparation:

A 10~ mucilage is prepared from potato starch by heating. The active substance, lactose and the remaining potato starch are mixed together and granulated with the above mucilage through a 1.5 mm mesh screen. The granules are dried at 45C, rubbed through the same screen again, mixed with magnesium stearate and compressed to form tablets.
Weight of tablet: 220 mg Punch: 9 mm Example VI

Cream for topical administration containing 1 g of trans-O-(4-chlorophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol A formulation for topical administration of the compounds of formula I may have the following composition:

1. Active substance 1.0 g 2. Stearyl alcohol 4.0 g 3. Cetyl alcohol 4.0 g 4. Mineral oil 3.0 g 5. Polysorbate 60 4.5 g 6. Sorbitan stearate 4.5 g 7. Propyleneglycol 10.0 g 8. Methylparaben 0.18 g 9. Propylparaben 0.02 g 10. Water q.s. ad 100.00 g Ingredients 2-6 are heated to 80C until they have all melted.
Then ingredient 1 is dissolved in the oily phase. Ingredients 7 and 10 are heated to 90C and ingredients 8 and 9 are 8~:8~

dissolved in the aqueous phase thus obtained. The aqueous phase is then added to the oil phase and quickly stirred to obtain an emulsion. The mixture is then slowly cooled to 50C
in order to solidify the emulsion. The preparation is cooled to ambient temperature whilst stirring is continued.

The following Example describes the preparation of a feed for laying hens:

Ex~m~le VII

Feed for laying hens containing as active substance trans-O-(4-chlorophenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol Maize 633 g/kg Soya bean flour 260 g/kg Meatmeal 40 g/kg Edible fat 25 g/kg Soya oil 17 g/kg Bicalcium phosphate 12 g/kg Calcium carbonate 6 g/kg Vitamin/mineral mixture 5 g/kg Active substance 2 g/kg These components in the quantities specified, when mixed thoroughly, yield 1 kg of feed.

Claims (15)

Claims
1. O-Acyl-4-phenyl-cycloalkanols of general formula I

(I) wherein n denotes the number 0 or 1, m denotes the number 1 or 2, p denotes the number 0 or 1, R1 and R2, which may be identical or different, denote a hydrogen atom, a straight-chained or branched C1-6-alkyl group, a straight-chained or branched C3-6-alkenyl or alkynyl group, the double and triple bonds thereof being isolated from the nitrogen-carbon bond, whilst the above-mentioned alkyl, alkenyl and alkynyl groups may also be substituted by an amino, hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, and the above-mentioned amino, hydroxy, alkoxy, alkylcarbonyloxy and alkylcarbonylamino group may not be bound to an unsaturated carbon atom and may not be bound to the carbon atom in position 1, or R1 and R2 together with the nitrogen atom between them denote a 5- to 7-membered saturated monocyclic heterocylic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed a methylene group in the 4-position may be replaced by an oxygen or sulphur atom or by an optionally alkyl-substituted imino group, R3 and R4, which may be identical or different, denote a hydrogen atom or a straight-chained or branched C1-4-alkyl group, R5 denotes a hydrogen atom, a straight-chained or branched C1-4-alkyl group or a C1-4-alkoxy group, R6 denotes a hydrogen atom or a straight-chained or branched C1-4-alkyl group, R7 denotes a hydrogen atom, a C3-7-cycloalkyl group, a phenyl group optionally mono- or disubstituted by a fluorine, chlorine or bromine atom or by a hydroxy, alkyl, alkoxy, phenylalkoxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkylcarbonylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkylcarbonyloxy, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group, wherein the substituents may be identical or different and two adjacent hydrogen atoms in a phenyl group may be replaced by a methylenedioxy or 1,2-ethylenedioxy group, a phenyl group substituted by two chlorine or bromine atoms and an amino group, a naphthyl or tetrahydronaphthyl group, a thienyl, furyl or pyridyl group substituted by a halogen atom or by one or two alkyl groups, and A denotes a bond, a straight-chained or branched C1-17-alkylene group or a C2-17-alkenylene or alkynylene group, whilst all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, and any halogen atom mentioned hereinbefore may be a fluorine, chlorine or bromine atom, the enantiomers, diastereomers and geometric isomers thereof and the salts thereof.
2. O-Acyl-4-phenyl-cyclohexanols of general formula Ia (Ia) wherein n, m and p each denote the number 1, R1 and R2, which may be identical or different, denote a hydrogen atom, a straight-chained or branched C1-6-alkyl group, a straight-chained or branched C3-6-alkenyl or alkynyl group, the double and triple bonds thereof being isolated from the nitrogen-carbon bond, whilst the above-mentioned alkyl, alkenyl and alkynyl groups may be substituted by an amino, hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, and the above-mentioned amino, hydroxy, alkoxy, alkylcarbonyloxy and alkylcarbonylamino group may not be bound to an unsaturated carbon atom and may not be bound to the carbon atom in position 1, or R1 and R2 together with the nitrogen atom between them denote a 5- to 7-membered saturated monocyclic heterocyclic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed a methylene group in the 4-position may be replaced by an oxygen or sulphur atom or by an optionally alkyl-substituted imino group, R3 to R6, which may be identical or different, each denote a hydrogen atom or a methyl group, R7 denotes a hydrogen atom, a C3-7-cycloalkyl group, a phenyl group optionally mono- or disubstituted by a fluorine, chlorine or bromine atom or by a hydroxy, alkyl, alkoxy, phenylalkoxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkylcarbonylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkylcarbonyloxy, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group, whilst the substituents may be identical or different and two adjacent hydrogen atoms in a phenyl group may be replaced by a methylenedioxy or 1,2-ethylenedioxy group, a phenyl group substituted by two chlorine or bromine atoms and an amino group, a naphthyl or tetrahydronaphthyl group, a thienyl, furyl or pyridyl group substituted by a chlorine or bromine atom or by one or two alkyl groups, and A denotes a bond, a straight-chained or branched C1-10-alkylene group or a C2-10-alkenylene or alkynylene group, wherein all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers thereof and the physiologically acceptable salts thereof with inorganic or organic acids.
3. O-Acyl-4-phenyl-cyclohexanols of general formula Ia according to claim 2, wherein n, m and p each denote the number 1, R1 denotes a hydrogen atom, a straight-chained or branched C1-4-alkyl group which may be substituted by an aminocarbonyl group or, in the 2-, 3- or 4-position, by a hydroxy or alkoxy group, or a 2-propenylene group, and R2 denotes a hydrogen atom, a C1-4-alkyl group or a 2-propenylene group, or R1 and R2 together with the nitrogen atom between them denote a 5- or 6-membered saturated monocyclic heterocyclic ring, whilst in a 6-membered saturated monocyclic heterocyclic ring thus formed, a methylene group in the 4-position may be replaced by an oxygen atom or by an optionally alkyl-substituted imino group, R3 to R6 each denote a hydrogen atom, R7 denotes a hydrogen atom, a C3-6-cycloalkyl group, a phenyl group optionally monosubstituted in the 4-position by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, phenyl, nitro or trifluoromethyl group, a phenyl group disubstituted by two chlorine atoms, one chlorine atom and an alkyl or amino group or two alkoxy groups, a phenyl group trisubstituted by two chlorine atoms and an amino group, a 3,4-methylenedioxyphenyl group, a naphthyl or tetrahydronaphthyl group, a 2-furyl group or a 2-thienyl group optionally substituted by a chlorine atom in the 5-position or a 3-pyridyl group, A denotes a bond, a straight-chained or branched C1-6-alkylene group or a C2-5-alkenylene group, whilst all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers thereof and the physiologically acceptable salts thereof with inorganic or organic acids.
4. O-Acyl-4-phenyl-cyclohexanols of general formula Ia according to claim 2, wherein n, m and p each denote the number 1, R1 denotes a hydrogen atom, a straight-chained or branched C1-4-alkyl group which may be substituted by an aminocarbonyl group or, in the 2-, 3- or 4-position, by a hydroxy or alkoxy group, or a 2-propenylene group, R2 denotes a hydrogen atom or a C1-4-alkyl group, R3 to R6 each denote a hydrogen atom, R7 denotes a phenyl group optionally substituted in the 4-position by a fluorine, chlorine or bromine atom or by a methyl, trifluoromethyl, methoxy, phenyl or nitro group, a 3,4-dichlorophenyl, 2,4-dichlorophenyl, 4-chloro-3-methylphenyl, 4-amino-3-chlorophenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-amino-3,5-dichlorophenyl or 2-naphthyl group, and A denotes a bond, a straight-chained or branched C1-5-alkylene group or a C2-3-alkenylene group, wherein all the above-mentioned alkyl and alkoxy moieties, unless otherwise specified, may contain 1 to 3 carbon atoms, the enantiomers, diastereomers and geometric isomers and the physiologically acceptable salts thereof with inorganic or organic acids.
5. As O-acyl-4-phenyl-cyclohexanols, the compounds:

(1) cis-O-(4-chlorobenozyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (2) cis-O-(4-phenyl-3-butenoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (3) trans-O-(4-chlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (4) cis-O-(5-methylhexanoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (5) trans-O-(2-phenylpropionyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (6) trans-O-(4-fluorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (7) trans-O-(3,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (8) cis-O-(4-fluorocinnamoyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (9) trans-O-(p-tolylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (10) trans-O-(4-[trifluoromethyl]-phenylacetyl)-4-(4-dimethylaminomethylphenyl)-cyclohexanol (11) trans-O-(2-naphthylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (12) trans-O-(4-nitrophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (13) trans-O-(4-bromophenylacetyl)-4-(4-dimethylaminomethyl-phenyl)-cyclohexanol (14) trans-O-(2,4-dichlorophenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol (15) trans-O-([4-amino-3-chlorophenyl]acetyl)-4-(4-dimethyl-aminomethylphenyl)-cyclohexanol (16) trans-O-(4-methoxyphenylacetyl)-4-(4-dimethylamino-methylphenyl)-cyclohexanol, (17) trans-O-(4-chlorophenylacetyl)-4-(4-methylaminomethyl-phenyl)-cyclohexanol, and the physiologically acceptable salts thereof with inorganic or organic acids.
6. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5 optionally together with one or more inert carriers and/or diluents.
7. Pharmaceutical compositions containing a compound according to at least one of claims 3 to 5 optionally together with one or more inert carriers and/or diluents.
8. Use of a compound according to at least one of claims 1 to 5 for the preparation of a pharmaceutical composition for inhibiting cholesterol biosynthesis.
9. Use of a compound according to at least one of claims 1 to 5 for preparing a pharmaceutical composition for the treatment or prophylaxis of hyperlipidaemias.
10. Use of a compound according to at least one of claims 1 to 5 for preparing a pharmaceutical composition for treating diseases connected with excessive cell proliferation.
11. Use of a compound according to at least one of claims 1 to 5 for preparing a pharmaceutical composition for the propylaxis and treatment of gallstone problems.
12. Use of a compound according to at least one of claims 1 to 5 for preparing a pharmaceutical composition for the treatment of mycoses.
13. Use of a compound according to at least one of claims 1 to 5, for preparing a feed for laying hens in order to produce low-cholesterol eggs.
14. Process for preparing a pharmaceutical composition according to claim 6 or 7, characterised in that a compound according to at least one of claims 1 to 5 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
15. Process for preparing compounds according to at least one of claims 1 to 5, characterised in that a) a 4-phenylcycloalkanol of general formula II

(II) wherein n, m, p and R1 to R6 are defined as in claims 1 to 4, is reacted with a carboxylic acid or the reactive derivatives thereof of general formula III

R7 - A - COX (III) wherein R7 and A are defined as in claims 1 to 4 and X denotes a hydroxy group or a reactive leaving group, at a temperature between -10 and 150°C, b) an O-acyl-4-phenylcycloalkanol of general formula IV

(IV) wherein n, m, p, R3 to R7 and A are defined as in claims 1 to 4 and Y
denotes a reactive leaving group is reacted with an amine of general formula V

(V) wherein R1 and R2 have the meanings given in claims 1 to 4, at a temperature between 0 and 100°C, or c) in order to prepare a compound of general formula I wherein R1 has the meanings given in claims 1 to 4 and R2 denotes a straight-chained or branched C1-6-alkyl group which may also be substituted by a hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, wherein the hydroxy, alkoxy, alkylcarbonyloxy or alkylcarbonylamino group is not bound to the carbon atom in position 1, an O-acyl-4-phenyl-cycloalkanol of general formula VI

(VI) wherein n, m, p, R3 to R7 and A are defined as in claims 1 to 4 and R1 is as hereinbefore defined, is reacted with a compound of general formula VII

R2' - Z1 (VII) wherein R2' denotes a straight-chained or branched C1-6-alkyl group which may be substituted by a hydroxy, alkoxy, alkylcarbonyloxy, alkylcarbonylamino, carboxyl, alkoxycarbonyl, aminocarbonyl or cyano group, wherein the hydroxy, alkoxy, alkylcarbonyloxy or alkylcarbonylamino group is not bound in position 1, and Z1 denotes a reactive leaving group, at temperatures between 0 and 100°C, and if necessary any hydroxy, amino, alkylamino or carboxyl group present in the compounds of formulae II to VII is protected by a protecting group which is cleaved again after the reaction has taken place, and/or compounds of general formula I thus obtained are converted into the salts thereof with inorganic or organic acids.
CA002188784A 1994-04-25 1994-04-25 O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them Abandoned CA2188784A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002188784A CA2188784A1 (en) 1994-04-25 1994-04-25 O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002188784A CA2188784A1 (en) 1994-04-25 1994-04-25 O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them

Publications (1)

Publication Number Publication Date
CA2188784A1 true CA2188784A1 (en) 1995-11-02

Family

ID=4159139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002188784A Abandoned CA2188784A1 (en) 1994-04-25 1994-04-25 O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them

Country Status (1)

Country Link
CA (1) CA2188784A1 (en)

Similar Documents

Publication Publication Date Title
US5455273A (en) N,N-disubstituted arylcycloalkylamines, the salts thereof, pharmaceutical compositions containing these compounds and the use thereof and processes for preparing them
US5616803A (en) Substituted amic acid derivatives
JPH04270261A (en) Isoprenoid phospholipase a2 inhibitor and preparation containing same
US5726205A (en) O-acyl-4-phenyl-cyclohexanols, their salts, medicaments containing such compounds and their use, as well as a method of preparing them
US5159114A (en) Acat inhibitory benzanilides
EP0824529A1 (en) Benzothiazoles and benzoxazoles, as well as drugs containing them, their use and methods of preparing them
US5962507A (en) O-acyl-4-phenyl-cyclohexanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them
CA2188784A1 (en) O-acyl-4-phenyl-cycloalkanols, their salts, medicaments containing such compounds, and their use, as well as a method of preparing them
KR100341037B1 (en) O-acyl-4-phenyl-cyclohexanol, salts thereof and pharmaceutical compositions containing the same
SK107393A3 (en) Aryliden-1-azacycloalkanes and arylalkyl-1-azacycloalkanes their salts, treatments compositions contained them compounds and their use and method of its production
JP4001317B2 (en) Novel urethanes, their thio analogs and dithio analogs, their salts, pharmaceutical compositions containing these compounds and their use and methods for their preparation
CZ311796A3 (en) O-acyl-4-phenyl-cycloalkanols, their salts, medicament in which the compounds are comprised and their use, as well as process for preparing thereof
HUT75706A (en) O-acyl-4-phenyl-cyclohexanols, medicaments containing such compounds and their use, as well as a method of preparing them
DE4438028A1 (en) New amino:alkyl substd. phenyl or phenoxy alkyl:amine cpds.
DE4438029A1 (en) New N,N-di:substd. benzo-cyclo-alkylamine derivs.
DE4421582A1 (en) New 4-(4-aminoalkylphenyl)cyclohexyl phenyl ketone derivs.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead